Literature DB >> 25465073

Frequent inactivation of SLIT2 and ROBO1 signaling in head and neck lesions: clinical and prognostic implications.

Guru Prasad Maiti1, Amlan Ghosh2, Pinaki Mondal3, Susmita Ghosh4, Jayanta Chakraborty5, Anup Roy6, Susanta Roychowdhury7, Chinmay Kumar Panda8.   

Abstract

OBJECTIVE: The protein SLIT2 and its receptor ROBO1 regulate different cellular processes, such as proliferation, apoptosis, and migration. In this study our aim is to understand the alterations of these genes during development of head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: First, molecular alterations of the genes were analyzed in 30 dysplastic lesions, 128 primary HNSCC samples, and 1 HNSCC cell line. Then alterations were correlated with mRNA expression (n = 22) and protein expression (n = 29). Finally, the alterations were correlated with different clinicopathologic parameters and clinical outcomes of the patients.
RESULTS: ROBO1 had a comparatively high frequency of deletion (28.5%-54.2%) from dysplastic lesions and subsequent clinical stages than did SLIT2 (16.6-27%). On the contrary, SLIT2 had a high frequency (56.6%-81.2%) of promoter methylation from dysplastic lesions onward compared with ROBO1 (20%-32.8%). Interestingly, alterations of SLIT2 and ROBO1 were high in dysplastic lesions (80%), followed by comparable frequencies (92.5%-95.3%) in subsequent stages of tumor. Alterations of these genes showed concordance with their mRNA/protein expression and significant association with poor patient outcome.
CONCLUSIONS: Our data suggest that inactivation of SLIT2 and/or ROBO1 is one of the early events in development of dysplastic lesions of head and neck and has prognostic importance.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25465073     DOI: 10.1016/j.oooo.2014.09.029

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  6 in total

1.  Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.

Authors:  Abeer A Alsofyani; Rawiah A Alsiary; Alaa Samkari; Baraa T Alhaj-Hussain; Jalaluddin Azam Khan; Jaudah Al-Maghrabi; Aisha Elaimi; Mohammed H Al-Qahtani; Adel M Abuzenadah; Ashraf Dallol
Journal:  J Appl Genet       Date:  2017-08-16       Impact factor: 3.240

2.  Frequent alterations of SLIT2-ROBO1-CDC42 signalling pathway in breast cancer: clinicopathological correlation.

Authors:  Rittwika Bhattacharya; Nupur Mukherjee; Hemantika Dasgupta; Md Saimul Islam; Neyaz Alam; Anup Roy; Priyobrata Das; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

3.  Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.

Authors:  Shreya Sarkar; Neyaz Alam; Syam Sundar Mandal; Kabita Chatterjee; Supratim Ghosh; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

4.  Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma.

Authors:  Yangyang She; Xiangbo Kong; Yaping Ge; Ping Yin; Zhiyong Liu; Jieyu Chen; Feng Gao; Silian Fang
Journal:  Cancer Cell Int       Date:  2020-01-17       Impact factor: 5.722

5.  Structural insights and evaluation of the potential impact of missense variants on the interactions of SLIT2 with ROBO1/4 in cancer progression.

Authors:  Debmalya Sengupta; Gairika Bhattacharya; Sayak Ganguli; Mainak Sengupta
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

6.  Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas.

Authors:  Saumya Srivastava; Ka Ming Pang; Mari Iida; Michael S Nelson; Jiayi Liu; Arin Nam; Jiale Wang; Isa Mambetsariev; Raju Pillai; Atish Mohanty; Nellie McDaniel; Amita Behal; Prakash Kulkarni; Deric L Wheeler; Ravi Salgia
Journal:  iScience       Date:  2020-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.